EHA2023

Cecilia BrownAcute Myeloid Leukemia | February 8, 2024
The NCRI AML18 trial evaluated the sequential addition of quizartinib to intensive chemotherapy in older adults with AML.
Cecilia BrownAcute Myeloid Leukemia | February 8, 2024
The “effect of gilteritinib was more pronounced” in patients who had detectable MRD than those who did not.
Cecilia BrownMyelofibrosis | July 14, 2023
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Advertisement
Cecilia BrownAcute Lymphoblastic Leukemia | July 7, 2023
The study included older patients with newly diagnosed Ph-negative CD22-positive B-lineage ALL.
Nico Gagelmann, MDVideo Insights | February 8, 2024
Dr. Gagelmann outlines the challenges that he sees in Europe and across the globe for young researchers and clinicians.
Leah SherwoodAcute Lymphoblastic Leukemia | February 8, 2024
The study showed that the infusion of obe-cel resulted in very low rates of Grade 3 or higher CRS and ICANS.
Advertisement
Leah SherwoodMyeloma | June 26, 2023
In this video interview from EHA, Dr, Munshi shares the close-out efficacy and safety results from CARTITUDE-1.
Nico Gagelmann, MDMeeting News | June 26, 2023
Dr. Gagelmann outlines key highlights of the session, his presentation and what he hopes attendees learned from the session.
Marco Ruella, MDMeeting News | February 8, 2024
A specific subset of antibiotics "were particularly bad" for the microbiome and were associated with poor survival.
Cecilia BrownMantle Cell Lymphoma | February 8, 2024
The study included 300 patients with advanced MCL who did not have clinically significant comorbidities.
Cecilia BrownPolycythemia Vera | June 26, 2023
The trial included patients with PV who had at least three therapeutic phlebotomies in the 28 weeks prior to enrollment.
Cecilia BrownMyelofibrosis | February 8, 2024
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Cecilia BrownMeeting News | September 20, 2023
Dr. Mascarenhas and colleagues identified 11,371 patients with myelofibrosis, finding that 76.8% had concurrent anemia.
Cecilia BrownMyeloproliferative Neoplasms | August 14, 2023
The median JAK2 mutant allele burden at baseline significantly differed among MPN subsets.
Cecilia BrownMeeting News | June 14, 2023
Dr. Kuykendall and colleagues presented their findings during the 2023 European Hematology Association Congress.
Leah SherwoodVideo Insights | June 14, 2023
Dr. Krecak presented the research during the 2023 EHA Congress.
Leah SherwoodMyelodysplastic Syndromes | July 20, 2023
KER-050 is a modified activin receptor type IIA ligand trap designed to inhibit select TGF-β superfamily ligands.
Thomas Martin, MDMeeting News | June 12, 2023
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
Leah SherwoodMyelodysplastic Syndromes | February 8, 2024
The study evaluated imetelstat versus placebo in patients with lower-risk MDS who were highly transfusion dependent.
Leah SherwoodMyelodysplastic Syndromes | February 8, 2024
Dr. Stéphane De Botton discusses his EHA abstract on tamibarotene-based therapy in MDS/AML.
Advertisement
Advertisement
Editorial Board